Unicycive Therapeutics, Inc. (UNCY) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Los Altos, CA, United States. El CEO actual es Shalabh K. Gupta.
UNCY tiene fecha de IPO 2021-07-12, 22 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $149.15M.
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
